iCAD's Participation in the Craig-Hallum Alpha Select Conference
NASHUA, N.H. – iCAD, Inc. (NASDAQ: ICAD) is excited to announce its participation in an upcoming important event, the Craig-Hallum Alpha Select Conference. This conference presents an exceptional occasion for institutional investors, where iCAD’s Chief Executive Officer, Dana Brown, and Chief Financial Officer, Eric Lonnqvist, will represent the company. Scheduled for a date in November, this conference will take place at Sheraton New York Times Square Hotel.
The Craig-Hallum Alpha Select Conference aims to be a platform for innovative ideas, highlighting over 90 public companies with attributes recognized by the Craig-Hallum research team. The criteria for selection include having a market cap under $500 million and being known for attractive business models with growth potential. iCAD, with its focus on AI-powered solutions for breast health, fits this profile remarkably well.
The Vision and Mission of iCAD
Founded with a passionate commitment to transforming cancer detection, iCAD, Inc. stands as a beacon of innovation in healthcare technology. The company’s mission is clear: to create a world where cancer can’t hide. With its AI-powered solutions, iCAD aims to empower medical professionals to detect cancer at its earliest stages, significantly improving patient outcomes and experiences.
The ProFound Breast Health Suite
At the core of iCAD's offerings is the ProFound Breast Health Suite, which is renowned for its revolutionary AI capabilities. This suite provides advanced mammography analysis designed for breast cancer detection and risk evaluation. Trusted by countless medical providers worldwide, the ProFound suite has made impressive strides, with the company estimated to have interpreted over 40 million mammograms globally in the last five years alone.
Global Reach and Impact
iCAD’s solutions have made their global mark, being utilized in over 50 countries and serving millions of patients. The widespread application demonstrates the reliability and effectiveness of their products in real-world scenarios, allowing for early cancer detection, which can lead to better treatment outcomes.
Engaging with Investors
At the Craig-Hallum Alpha Select Conference, iCAD management will be available for one-on-one meetings with interested investors. This offers a valuable opportunity for investors to discuss iCAD's commitment to innovation and its strategies for future growth. Those wishing to meet can reach out to their Craig-Hallum representatives for arrangements.
Why iCAD Matters in Today's Healthcare Landscape
The importance of early cancer detection in today's healthcare cannot be overstated. With rising cancer cases globally, technologies that enable early diagnosis are critical. iCAD’s innovative solutions are not merely products; they represent a shift toward intelligent healthcare systems that prioritize patient wellbeing. Through AI, iCAD continues to seek ways to enhance diagnostic accuracy and reduce the anxiety often associated with cancer screenings.
Strengthening Patient Trust
Trust in medical technologies is paramount, and iCAD’s commitment to quality and reliability assures patients that their health is in capable hands. With their state-of-the-art technology, patients can feel confident that healthcare providers have the tools to make informed decisions regarding cancer screening and diagnosis.
Looking to the Future
As iCAD moves forward, the company is not just focusing on providing solutions but also on expanding access to their powerful technologies. The combination of commitment to quality, technological advancement, and responsive customer support positions iCAD as a leader in the healthcare industry.
Frequently Asked Questions
What is the Craig-Hallum Alpha Select Conference?
The Craig-Hallum Alpha Select Conference is a networking event for institutional investors featuring selected public companies noted for their growth potential.
Who are the representatives of iCAD at the conference?
Dana Brown (CEO) and Eric Lonnqvist (CFO) will represent iCAD at the conference.
What is the mission of iCAD?
iCAD aims to create a world where cancer can’t hide by providing clinically proven AI-powered solutions for early cancer detection.
What is the ProFound Breast Health Suite?
The ProFound Breast Health Suite is iCAD’s signature product, offering AI-powered mammography analysis for breast cancer detection.
How many mammograms has iCAD interpreted globally?
iCAD estimates that it has interpreted more than 40 million mammograms worldwide in the last five years, enhancing early detection efforts.
